Total Support by a Trans-Aortic Valve Micro-Axial Flow Pump Reduces Coronary Blood Flow in Both Normal and Post-reperfusion Coronary Arteries in a Goat Model of Ischemia-Reperfusion
Abstract Body (Do not enter title and authors here): Introduction In cases of cardiogenic shock, the transaortic micro-axial flow pump (Impella) improves systemic circulation and increases coronary perfusion pressure (CPP) while reducing myocardial oxygen consumption (MVO2) via its left ventricular (LV) unloading effect. The Impella 5.5, in particular, enables stronger LV unloading due to its higher flow capacity. Physiologically, coronary blood flow (CBF) increases with CPP, while reduced MVO2 may activate autoregulatory mechanisms that limit CBF. Hypothesis We hypothesized that a marked reduction in MVO2 by the Impella 5.5 may attenuate CBF. This study evaluates the impact of Impella 5.5 support on CBF in normal and post-reperfusion coronary arteries using a goat model of ischemia-reperfusion. Methods Saanen goats (N=8, BW: 61.6±4.5 kg) were used under general anesthesia. The Impella 5.5 was inserted via the carotid artery into the LV. We measured blood pressure, LV pressure, pulmonary artery flow, arterial and coronary sinus oxygen saturation, and CBF in the left anterior descending artery (LAD) and left circumflex artery (LCX). We occluded the proximal LAD with a 3 mm balloon for 90 minutes, then deflated for reperfusion (Fig. A). At 30-min after reperfusion, Impella support was set at three stages: Control (P1), Partial support with residual native cardiac output (P3-7), and Total support (P6-9). Results Increasing Impella support augmented CPP (37.8 ± 10.6 vs. 47.1 ± 8.5 vs. 75.2 ± 12.7 mmHg, P < 0.05) and reduced MVO2 (298.3 ± 161.0 vs. 257.9 ± 122.2 vs. 161.0 ± 121.6, P < 0.05) (Fig. B). Total support with the Impella 5.5 suppressed MVO2 by 53.0 ± 18.8% compared to the Control condition. LCX flow decreased with increasing Impella support (46.9 ± 26.6 vs. 45.0 ± 28.5 vs. 37.8 ± 31.0 mL/min, P < 0.05). Similarly, LAD flow was significantly reduced under Total support (30.9 ± 11.4 vs. 28.5 ± 11.7 vs. 23.7 ± 12.2 mL/min, P < 0.05) (Fig. C). Conclusion In a goat model of ischemia–reperfusion, total support with the Impella 5.5 reduced CBF in both the normal LCX and the injured LAD. These results may be influenced by factors such as the severity of coronary injury, the timing of measurement, and the specific animal model used. Nevertheless, the findings suggest that autoregulatory mechanisms triggered by suppressed MVO2 play a critical role in determining CBF, even in post-reperfusion setting, and should be carefully considered when evaluating the effects of Impella5.5 support on coronary circulation.
Ohba, Kenta
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Kawada, Toru
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Saku, Keita
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Otake, Masahiro
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Hiraki, Nana
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Yoshida, Yuki
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Morita, Hidetaka
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Sato, Kei
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Nishikawa, Takuya
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Fukumitsu, Masafumi
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Uemura, Kazunori
( National Cerebral and Cardiovascular Center
, Suita, Osaka
, Japan
)
Author Disclosures:
Kenta Ohba:DO NOT have relevant financial relationships
| Toru Kawada:No Answer
| Keita Saku:DO have relevant financial relationships
;
Advisor:Cubec:Active (exists now)
; Research Funding (PI or named investigator):Zeon Medical Inc.:Active (exists now)
; Research Funding (PI or named investigator):Neuroceuticals Inc.:Active (exists now)
; Research Funding (PI or named investigator):Asahi Kasei ZOLL Medical Corporation:Active (exists now)
; Research Funding (PI or named investigator):NTT Research:Active (exists now)
; Research Funding (PI or named investigator):Abiomed Inc.:Active (exists now)
; Speaker:Mallinckrodt Pharma K.K.:Active (exists now)
; Speaker:Abiomed Japan K.K.:Active (exists now)
; Advisor:WION:Active (exists now)
| Masahiro Otake:DO NOT have relevant financial relationships
| NANA HIRAKI:DO NOT have relevant financial relationships
| Yuki Yoshida:DO NOT have relevant financial relationships
| Hidetaka Morita:DO NOT have relevant financial relationships
| Kei Sato:DO NOT have relevant financial relationships
| Takuya Nishikawa:DO NOT have relevant financial relationships
| Masafumi Fukumitsu:DO NOT have relevant financial relationships
| Kazunori Uemura:DO NOT have relevant financial relationships